Bristol Myers Squibb Reports CheckMate-816 Pathological Response Data for Opdivo in NSCLC

Bristol Myers Squibb today presented pathological complete response data from the Phase 3 CheckMate-816 trial evaluating neoadjuvant Opdivo (nivolumab) plus chemotherapy in patients with resectable non-small cell lung cancer. The trial demonstrated a significantly higher rate of pathological complete response with Opdivo plus chemotherapy compared to chemotherapy alone, with 24% of patients achieving pCR versus 2.2%.